Tower Research Capital LLC TRC lifted its stake in Vaxart, Inc. (NASDAQ:VXRT – Get Rating) by 147.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,073 shares of the biotechnology company's stock after acquiring an additional 51,953 shares during the quarter. Tower Research Capital LLC TRC owned approximately 0.07% of Vaxart worth $190,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of VXRT. State Street Corp increased its stake in shares of Vaxart by 23.9% in the first quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company's stock worth $69,859,000 after acquiring an additional 2,673,332 shares during the last quarter. Barclays PLC increased its position in Vaxart by 6,969.5% during the third quarter. Barclays PLC now owns 656,117 shares of the biotechnology company's stock worth $1,430,000 after buying an additional 646,836 shares during the last quarter. UBS Group AG increased its position in Vaxart by 34.6% during the first quarter. UBS Group AG now owns 836,815 shares of the biotechnology company's stock worth $4,217,000 after buying an additional 214,901 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Vaxart by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 434,678 shares of the biotechnology company's stock worth $2,191,000 after buying an additional 214,197 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Vaxart by 28.7% during the first quarter. Bank of America Corp DE now owns 631,861 shares of the biotechnology company's stock worth $3,185,000 after buying an additional 140,833 shares during the last quarter. 38.66% of the stock is owned by institutional investors and hedge funds.
Get Vaxart alerts:Analysts Set New Price Targets
Separately, B. Riley lowered their target price on shares of Vaxart from $6.00 to $1.50 and set a "neutral" rating on the stock in a research report on Monday, December 19th.
Vaxart Price Performance
Vaxart stock opened at $0.81 on Tuesday. The company has a market capitalization of $105.79 million, a price-to-earnings ratio of -0.97 and a beta of 0.82. The company's fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.57. Vaxart, Inc. has a one year low of $0.73 and a one year high of $5.43.
Vaxart Profile
(Get Rating)
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection.
Featured Articles
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- Go Where the Money Is. Here's 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT – Get Rating).
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.